Clinical Endpoint Bioequivalence study [Regulatives / Guidelines]

posted by sury – India, 2019-04-08 13:29 (598 d 12:26 ago) – Posting: # 20130
Views: 2,256

Hii all
Hope all are doing well!
I have recently got an bioequivalence study with clinical endpoints for some drug
In OGD it states that

“To establish bioequivalence, the 90% confidence interval of the test/reference ratio of the mean should be contained within [0.80, 1.25], using the per protocol (PP) population.”

The scores of the clinical endpoint shall be as follows
“Score the oral lesions and specific signs and symptoms of oropharyngeal candidiasis at each visit using the following two scoring systems:
  1. Oral lesions score (Murray scale)
    0=none
    1=single, localized
    2=multiple, localized
    3=extensive, confluent
  2. Signs and Symptoms score (e.g., erythema, thrush, mucositis, odynophagia, burning/soreness, xerostomia, modified taste, pharyngeal irritation)
    0=absent
    1=mild
    2=moderate
    3=severe”
For the above, do we need to convert the grading (0,1,2,3) to log transformed data and conduct the statistical analysis?

As the above states that 20% difference is accepted, then in normal bioequivalence case (if untransformed data), it should be 80.00-120.00?


Correct me if I am wrong?


Best regards

Complete thread:

Activity
 Admin contact
21,213 posts in 4,426 threads, 1,483 registered users;
online 15 (0 registered, 15 guests [including 9 identified bots]).
Forum time: Friday 00:56 CET (Europe/Vienna)

Biostatistician. One who has neither the intellect for mathematics
nor the commitment for medicine but likes to dabble in both.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5